Trial reportAntimicrobial agents and chemotherapy2001
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
Trial report in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.British journal of clinical pharmacology · 2016Trial
- Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.Journal of clinical pharmacy and therapeutics · 2013Trial
- Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Antimicrobial agents and chemotherapy · 2011Trial
- Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Antimicrobial agents and chemotherapy · 2010Trial
- Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.Antimicrobial agents and chemotherapy · 2004Trial
- Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Antimicrobial agents and chemotherapy · 2003Trial
- Trace-level quantification of levofloxacin NDSRIs using LC-TQ-MS/MS: a multi-metric sustainability and integrated toxicological-analytical framework.BMC chemistry · 2026Article
- Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Mutant Prevention Concentrations of Ciprofloxacin and Levofloxacin and Target Gene Mutations of Fluoroquinolones in Elizabethkingia anophelis.Antimicrobial agents and chemotherapy · 2022Article
- MRGPRX2 and Adverse Drug Reactions.Frontiers in immunology · 2021Review
- Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.Antimicrobial agents and chemotherapy · 2017Article
- Antibiotic dosing in critically ill patients with acute kidney injury.Nature reviews. Nephrology · 2011Review
- Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.Drug, healthcare and patient safety · 2011Article
- Pharmacokinetics and pharmacodynamics of antibacterial agents.Infectious disease clinics of North America · 2009Review
- Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2009Article
- Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.Antimicrobial agents and chemotherapy · 2009Article
- Clinical pharmacokinetics and pharmacodynamics of tigecycline.Clinical pharmacokinetics · 2009Review
- Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety and pharmacokinetics of a once-daily high intravenous dose of levofloxacin (750 mg) in 18 healthy volunteers were studied in a double-blind, randomized, placebo-controlled, single-center parallel group study. Levofloxacin was well tolerated, and higher maximum concentration of drug in serum and area under the concentration-time curve values were achieved. For difficult-to-treat infections, high daily doses of levofloxacin may be beneficial, and intravenous administration may be preferred in certain clinical settings, such as when treating patients in intensive care units, warranting further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.